Bristol-Myers Squibb Company (NYSE:BMY) – Analysts at SunTrust Banks boosted their FY2017 EPS estimates for Bristol-Myers Squibb in a report released on Monday. SunTrust Banks analyst J. Boris now forecasts that the biopharmaceutical company will post earnings of $3.00 per share for the year, up from their previous estimate of $2.95. SunTrust Banks also issued estimates for Bristol-Myers Squibb’s FY2018 earnings at $3.17 EPS and FY2019 earnings at $3.62 EPS.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The business had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. During the same period last year, the business posted $0.69 EPS. Bristol-Myers Squibb’s revenue was up 5.6% on a year-over-year basis.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2017/10/20/bristol-myers-squibb-company-forecasted-to-post-fy2017-earnings-of-3-00-per-share-bmy.html.

Several other research analysts have also recently weighed in on BMY. Citigroup Inc. boosted their price target on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a report on Wednesday. BidaskClub upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. Jefferies Group LLC cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price target on the stock. in a report on Monday. Finally, Vetr cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 price target on the stock. in a report on Thursday, September 28th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the company. Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus price target of $63.79.

Shares of Bristol-Myers Squibb (NYSE BMY) traded down 0.37% during midday trading on Thursday, reaching $64.43. 1,956,494 shares of the company traded hands. The company has a 50-day moving average of $63.26 and a 200 day moving average of $57.22. The firm has a market capitalization of $105.66 billion, a PE ratio of 23.53 and a beta of 1.19. Bristol-Myers Squibb has a 12-month low of $46.01 and a 12-month high of $66.10.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Blue Chip Partners Inc. raised its position in shares of Bristol-Myers Squibb by 0.7% in the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 15 shares during the period. Jackson Grant Investment Advisers Inc. raised its position in shares of Bristol-Myers Squibb by 0.4% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 15 shares during the period. Keel Point LLC raised its position in shares of Bristol-Myers Squibb by 0.3% in the first quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 18 shares during the period. Staley Capital Advisers Inc. raised its position in shares of Bristol-Myers Squibb by 0.3% in the first quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock valued at $379,000 after purchasing an additional 24 shares during the period. Finally, Shayne & CO. LLC raised its position in shares of Bristol-Myers Squibb by 0.6% in the second quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 24 shares during the period. 68.84% of the stock is currently owned by institutional investors.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the sale, the senior vice president now owns 46,297 shares of the company’s stock, valued at $2,777,820. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Theodore R. Samuels II purchased 6,000 shares of the stock in a transaction dated Wednesday, August 2nd. The stock was acquired at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the transaction, the director now owns 18,000 shares of the company’s stock, valued at $1,006,920. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 2.41%. The ex-dividend date of this dividend is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 56.73%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.